YN440309 c-Kit-IN-1 1225278-16-9

DCC-2618 is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of KIT and PDGFR with potential antineoplastic activity. It also inhibits several other kinases, including VEGFR2, TIE2, P...

YN440274 AC710 1351522-04-7

AC710 is a potentPDGFRinhibitor withKds of 0.6, 1.57, 1, 1.3, 1.0nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

YN440156 Ripretinib 1442472-39-0

DCC-2618 is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and PDGFR-alpha, with IC50 ...

YN440036 Avapritinib 1703793-34-3

Avapritinib (BLU-285) is a highly potent, selective, and orally activeKIT and PDGFRAactivation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24nM forKIT D816V and PDGFRA D842V, respectively. Avapri...

YN440160 AZD3229 2248003-60-1

AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines (GI50=1-50 nM), with good margin to KDR-driven effects. It a...

YN440161 AZD3229 Tosylate 2248003-71-4

AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

YN440227 c-Kit-IN-3 2363169-01-9

c-Kit-IN-3 (Compound 18) is a potent and selectivec-KIT kinaseinhibitor with anIC50s of 4nM, 8nM for c-KIT wt and c-KIT T670I, respectively. c-Kit-IN-3 displays great potencies against most of the gain-offunction m...

YN440128 Lenvatinib

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGF...